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REVIEWThe Brain-Gut-Microbiome Axis
Clair R. Martin, Vadim Osadchiy, Amir Kalani, and Emeran A. Mayer
G. Oppenheimer Center for Neurobiology of Stress and Resilience, Vatche and Tamar Manoukian Division of Digestive
Diseases, Microbiome Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CaliforniaAbbreviations used in this paper: ANS, autonomic nervous system;
ASD, autism spectrum disorder; BBB, blood-brain barrier; BGM, brain-
gut-microbiome; CNS, central nervous system; ECC, enterochromaffin
cell; EEC, enteroendocrine cell; FFAR, free fatty acid receptor; FGF,
fibroblast growth factor; 5-HT, serotonin; FXR, farnesoid X receptor;
GF, germ-free; GI, gastrointestinal; GLP-1, glucagon-like peptide-1;
GPR, G-protein–coupled receptor; IBS, irritable bowel syndrome; LPS,
lipopolysaccharide; SCFA, short-chain fatty acid; SPF, specific-
pathogen-free; TGR5, G protein-coupled bile acid receptor; Trp, tryp-
tophan; 2BA, secondary bile acid.
Most current articleSUMMARY
The past decade has seen a paradigm shift in our
understanding of the brain-gut axis. The exponential growth
of evidence detailing the bidirectional interactions between
the gut microbiome and the brain supports a comprehensive
model that integrates the central nervous, gastrointestinal,
and immune systems with this newly discovered organ. Data
from preclinical and clinical studies have shown remarkable
potential for novel treatment targets not only in functional
gastrointestinal disorders but in a wide range of psychiatric
and neurologic disorders, including Parkinson’s disease,
autism spectrum disorders, anxiety, and depression, among
many others.
Preclinical and clinical studies have shown bidirectional
interactions within the brain-gut-microbiome axis. Gut
microbes communicate to the central nervous system
through at least 3 parallel and interacting channels
involving nervous, endocrine, and immune signaling
mechanisms. The brain can affect the community structure
and function of the gut microbiota through the autonomic
nervous system, by modulating regional gut motility,
intestinal transit and secretion, and gut permeability, and
potentially through the luminal secretion of hormones that
directly modulate microbial gene expression. A systems
biological model is proposed that posits circular commu-
nication loops amid the brain, gut, and gut microbiome,
and in which perturbation at any level can propagate
dysregulation throughout the circuit. A series of largely
preclinical observations implicates alterations in brain-
gut-microbiome communication in the pathogenesis and
pathophysiology of irritable bowel syndrome, obesity, and
several psychiatric and neurologic disorders. Continued
research holds the promise of identifying novel therapeutic
targets and developing treatment strategies to address
some of the most debilitating, costly, and poorly understood
diseases. (Cell Mol Gastroenterol Hepatol 2018;6:133–148;
https://doi.org/10.1016/j.jcmgh.2018.04.003)
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https://doi.org/10.1016/j.jcmgh.2018.04.003Rthe past decade strongly support the concept of
bidirectional brain-gut-microbiome (BGM) interactions.
Alterations in these interactions have been implicated not
only in the pathogenesis and pathophysiology of classic
brain-gut disorders such as irritable bowel syndrome (IBS)and other functional gastrointestinal disorders,1,2 but a
growing list of psychiatric and neurologic pathologies
including affective disorders,3,4 autism spectrum disorders
(ASD),3,5 Parkinson’s disease,6 multiple sclerosis,7 and
chronic pain.8 Although most of the literature associates gut
microbiota composition with human health, development,
and disease, evidence for causality remains sparse. The BGM
axis’ interface with fundamental and disease-susceptible
processes make it a novel therapeutic target, but this
network remains insufficiently understood for intervention.
In this review, we address current evidence supporting
bottom-up and top-down signaling within the BGM axis
and the emerging evidence supporting its contribution to
human disease.
BGM State of the Science
Preclinical Evidence
Several experimental approaches in animal models have
been used to study the influence of gut microbiota on the
BGM axis, including manipulation with antibiotics,9 fecal
microbial transplantation,9,10 colonization with synthetic11
or human12,13 microbiota, cultured gut organ systems,14,15
probiotic administration,16 and germ-free (GF) animal
models.17 Despite limitations to these approaches, signifi-
cant progress has been made since Sudo et al17 first showed
that the absence of normal gut microbiota early in life has
significant effects on stress responsiveness in the adult and
that these changes can be partially reversed by early colo-
nization of the gut with conventional microbiota, even a
single species. Subsequent investigations have further
characterized the associated neurochemical changes,
including altered cortical and hippocampal brain-derived
neurotrophic factor levels,17,18 reduced hippocampal sero-
tonin (5-HT) receptor 1A expression,18 increased striatal
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gene expression,19 showing the microbiome’s diverse and
potent influence over central nervous system (CNS)
phenotypes. Accordingly, in addition to stress responsive-
ness,16,20 the gut microbiota are implicated in relation
to anxiety-like16,18–28 and depression-like behav-
ior,16,24,25,27,29–32 nociceptive response,8,33–37 feeding
behavior, taste preference, metabolic consequences,38–40
and their respective underlying physiologies. These pre-
clinical studies have been reviewed extensively in the lit-
erature.3,5,41–43 Despite acknowledged limitations to the GF
model,28,41,44 phenotype reversal by recolonization with
specific-pathogen-free (SPF), human-derived, and synthetic
microbiota validates some of the conclusions. Still, the
well-characterized role of microbiota in neurogenesis and
neurodevelopment45 moderates the translational relevance
of these findings for adult conditions.
An alternative to the GF model approach is the use of
broad-spectrum antibiotics to induce transient changes on
the composition and diversity of fecal microbiota,9 although
the effects on mucosa-associated microbial communities are
incompletely understood. Antimicrobials also may interact
directly with host physiology in mechanisms independent of
the microbiome, such as their well-documented neurotoxic
effects (reviewed by Grill and Maganti46). Nonetheless,
broad-spectrum antibiotic treatment remains a powerful
tool to identify gut microbial influence on the CNS. In mice
with SPF microbiota, oral antibiotic administration
increased exploratory behavior and hippocampal expression
of brain-derived neurotrophic factor, which was associated
with changes in the microbial profile.9 The failure to repli-
cate these antibiotic-induced effects in GF mice suggests
the CNS changes are not the result of off-target antibiotic
interactions, however, developmental alterations in the GF
model make this finding inconclusive. Long-term antibiotic
treatment in adult mice reduced hippocampal neurogenesis
and lead to deficits in novel object recognition tasks through
a mechanism dependent on circulating monocytes.47 Adop-
tive transfer of Ly-6chi monocytes or voluntary exercise and
probiotic treatment rescued these phenotypes.47
In contrast to the complete or partial depletion of gut
microbiota as an experimental approach to identify and
characterize microbial influence on the host CNS, the
introduction of known microorganisms (usually as pro-
biotics) to conventional models allows for normal develop-
ment and risks fewer off-target effects. However, it is critical
to acknowledge the possibility that transient exposure
induces host responses inaccessible to resident commu-
nities. Orally administered probiotics have been shown to
reduce basal or induced anxiety-like behavior,16,20,22,24,30,48
attenuate induced obsessive-compulsive–like behavior,49
improve inflammation-associated sickness behavior,50 and
even normalize developmental trajectories of emotion-
related behavior after early life stress.51 Although infre-
quently used as an intervention directed specifically at the
gut microbiota, diet can have profound, rapid, and repro-
ducible effects on the structure of the gut microbiota in
human beings and mice.52–54 Alterations in the gut micro-
bial community through dietary change also have beenshown to influence memory and learning,55,56 while pro-
biotic administration rescued diet-induced memory deficits
in rats.57 In summary, preclinical studies have identified
unequivocally the potent influence of gut microbiota on the
CNS, but issues of reproducibility and off-target intervention
effects demand continued improvement of experimental
approaches.
Clinical Evidence
Experimental approaches to study the role of gut
microbes to brain signaling have been restricted mostly to
small clinical studies showing the association of gut micro-
bial community structure with brain parameters and sub-
jective outcomes of interventions with probiotics and
prebiotics. Although no high-quality, controlled studies in
human beings have reported the effects of interventions
such as antibiotics or fecal microbial transplants on the
brain or behavior, studies of probiotic interventions are
increasing rapidly in number and gradually in scale and
quality. A double-blind, placebo-controlled, pilot study of
the probiotic Bifidobacterium longum NCC3001 in 44 adults
with IBS and diarrhea was shown to reduce responses in the
amygdala and frontolimbic regions to negative emotional
stimuli as measured by functional magnetic resonance im-
aging.58 Although depression scores were lower with the
intervention, anxiety and IBS symptoms were not affected.
In healthy female control subjects, consumption of a fer-
mented milk product with probiotics over 4 weeks was
associated with significant changes in the functional con-
nectivity between brain regions during an emotion recog-
nition task, notably without concomitant detectable changes
in gut microbial composition.59 Probiotic consumption also
has been reported to reduce self-reported feelings of
sadness and aggressive thoughts.60 A probiotic cocktail used
to achieve reduction of anxiety- and depression-related
behaviors in mice48 also was administered to healthy hu-
man beings to a similar effect.61
The translation of promising findings obtained in rodent
studies has been limited. In a clinical trial with Lactobacillus
rhamnosus (JB-1), the effects of which were seminally
shown on mice by Bravo et al,16 performed no better than
placebo on stress-related measures, hypothalamic pituitary
adrenal axis response, inflammation, or cognitive perfor-
mance in an 8-week trial with healthy males.62 Moreover,
the pilot trial of Bifidobacterium longum NCC3001
described earlier did not recapitulate the effects observed in
mice by the same research group22 and has been criticized
for its fragility.63 This translational disconnect, or inconsis-
tency, highlights the likelihood of host-specific microbiota
interactions and underscores the importance of cautious
extrapolation of preclinical findings. Furthermore, as shown
by several studies, probiotic supplementation in human
beings does not appear to change the gut’s microbiota
composition but induces its effect on behavior via transient
modification of the collective microbiome transcriptional
state, as shown in GF mice and confirmed in monozygotic
twins.64 This finding demands measurement of probiotic
intervention on gut microbial profiles with technologies
integrating metatranscriptomics and metabolomics and
2018 BGM Axis 135fundamental reconsideration of the functional equivalence
of transient vs resident microorganisms. Better character-
ization of microbial community dynamics and metabolism
coupled with improved models of their community ecology
will help refine the mechanisms responsible for these effects
and identify putative targets for therapeutic intervention.Signaling Mechanisms From the Gut
Microbiota to the Brain
Current evidence indicates that bottom-up modulation
of the CNS by the microbiome occurs primarily through
neuroimmune and neuroendocrine mechanisms, often
involving the vagus nerve.16,65–67 This communication is
mediated by several microbially derived molecules that
include short-chain fatty acids (SCFAs), secondary bile acids
(2BAs), and tryptophan metabolites.65,68,69 These molecules
propagate signals primarily through interaction with
enteroendocrine cells (EECs), enterochromaffin cells (ECCs),
and the mucosal immune system, but some cross the
intestinal barrier, enter systemic circulation, and may cross
the blood-brain barrier.68,70,71 It remains poorly understood
if these molecules reach brain sites directly or only induce
central responses via long-distance neural signaling by vagal
and/or spinal afferents.16,72 In addition to generating these
metabolites that activate endogenous CNS signaling mech-
anisms, the microbiota can independently produce or
contribute to the production of a number of neuroactive
molecules including but not limited to g-aminobutyric
acid,73,74 5-HT,75,76 norepinephrine,76,77 and dopamine,75–77
although it is unknown if they reach relevant receptors or
achieve sufficient levels to elicit a host response.Neuroendocrine and Enteroendocrine
Signaling Pathways
An important pathway by which gut microbes and their
metabolites communicate with the CNS involves the cells
making up the endocrine system of the gut.78 There are at
least 12 different types of these cells with several subtypes
(in particular A, K, and L cells) present as subgroups along
the intestine that contain different combinations of mole-
cules. EECs are interspersed between gut epithelial cells
throughout the length of the gut and contain more than 20
different types of signaling molecules, which often are
colocalized and co-released. Released in response to chem-
ical and or mechanical stimuli, these molecules can enter the
systemic circulation and reach centers in the CNS involved
in ingestive behavior (including the nucleus tractus sol-
itarius and the hypothalamus) or act locally and activate
closely adjacent afferent vagal terminals in the gut or liver
to generate brain signals. A series of receptors involved in
the regulation of satiety and hunger have been identified on
these cells, which are activated by microbial metabolites
including bile acids and SCFAs.
Although bile acids are endogenous molecules synthe-
sized from cholesterol in the liver, the size and composi-
tion of the host’s pool of these molecules is heavily
influenced by dietary intake, especially of fat,79 and thedownstream metabolism by the gut microbiota (reviewed
by de Aguiar et al80 and Wahlstrom et al81). Ileal expres-
sion of farnesoid X receptor (FXR), a nuclear receptor, is
activated by bile acids leading to production of fibroblast
growth factor 19 (FGF19), or its similarly functioning
ortholog FGF15 in mice, which can enter the systemic
circulation and cross the blood-brain barrier.82 Activation
of the arcuate nucleus of the hypothalamus by the FXR/
FGF19 action on agouti-related peptide/neuropeptide Y83
has been implicated in improved central regulation of
energy and glucose metabolism84–86 and suppression of
hypothalamic pituitary adrenal axis activity.87 Some in-
testinal L cells express surface receptor G protein-coupled
bile acid receptor (TGR5), which is activated mostly by
secondary bile acids, which are strongly influenced by
microbial activity.88,89 TGR5 signaling controls glucose
homeostasis by mechanisms including increased glucagon-
like peptide-1 (GLP-1) release by these L cells.90 Inter-
estingly, these L cells also express FXR, which can regulate
GLP-1 synthesis.91
SCFAs have been implicated as major signaling
molecules mediating host-microbe communication via EECs
and ECCs. These molecules are generated by microbial
fermentation of host dietary-resistant starch and nonstarch
polysaccharides and serve an important part in the host’s
energy harvest while also stimulating colonic blood flow,
fluid and electrolyte uptake, and mucosal proliferation.92
Dietary fiber intake is a major regulator of SCFA concen-
trations. In instances in which the host diet is low in
fermentable fibers, microbes feed on mucus glycans and use
alternative, less energetically favorable sources, resulting
in reduced fermentative activity and SCFA production.93
Both preclinical and clinical data have shown that microbi-
al activity, in particular the production of SCFAs, stimulate
L cells located at the distal ileum to secrete peptide YY and
GLP-1, which induce satiety and behavioral changes.65,70,94
Acetate, butyrate, and propionate modulate the expression
and secretion of GLP-1 via free fatty acid receptor 2
(FFAR2)/G-protein–coupled receptor 43 (GPR43) and
FFAR3/GPR41 on L cells,65 and GPR41s have been identified
on different EECs in the gut.95 This widespread distribution
of these receptors on and in EECs and ECCs involved in the
regulation of food intake and digestion is consistent with
the important role of the gut microbes in these processes
and the expectations of holobiont co-evolution.
Enterochromaffin Cell Signaling
One of the best characterized examples of these
microbial host interactions is the bidirectional interaction
between microbes, ECCs, and the central nervous system
(Figure 1). 5-HT is produced by the ECCs of the gastroin-
testinal (GI) tract, with 95% of the body’s 5-HT stored in
ECCs and enteric neurons, and only 5% stored in the CNS.96
Considering 5-HT’s central role in regulating GI motility and
secretion, there is likely immense selective pressure on the
gut microorganisms to act on the serotonergic system to
modulate their environment effectively (eg, by influencing
regional transit times and fluid secretions). An analysis of
the plasma metabolite profile of germ-free mice shows a
Figure 1. Bidirectional
brain-gut-microbiome
interactions related to
serotonin signaling.
Enterochromaffin cells
(shown in green) contain
more than 90% of the
body’s serotonin (5-HT).
5-HT synthesis in ECCs is
modulated by SCFAs and
2BAs produced by spore-
forming Clostridiales,
which increase their stim-
ulatory actions on ECCs
with increased dietary
tryptophan availability.68
ECCs communicate with
afferent nerve fibers
through synapse-like con-
nections between
neuropod-like extensions
and afferent nerve termi-
nals.192 The autonomic
nervous system can acti-
vate ECCs to release 5-HT
into the gut lumen, where it
can interact with gut mi-
crobes.155 TPH1, trypto-
phan hydroxylase type 1.
136 Martin et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 2more than 2-fold decrease in 5-HT levels relative to
conventionally colonized mice.69 SCFAs and 2BAs derived
from spore-forming bacteria of the gut regulate a significant
percentage of ECC 5-HT synthesis and release.68 The
essential amino acid tryptophan (Trp) is a key molecule in
the BGM axis because it is the precursor to the neuro-
transmitter 5-HT and a number of other metabolites that
contribute to the neuroendocrine signaling within the
BGM.97 Because the host is unable to produce tryptophan,
dietary intake of proteins that contain it serve as the pri-
mary regulator of its availability. Gut microbiota contribute
to the peripheral availability of Trp, which is imperative to
the CNS synthesis of 5-HT. GF mice show increased levels of
plasma Trp and hippocampal 5-HT, and, interestingly,
colonization with bacteria normalizes plasma Trp but not
hippocampal 5-HT.21 Although the exact mechanisms of
peripheral Trp regulation are unknown, the same study
suggests that the microbiota modulate the degradation
of Trp down the kynurenine pathway. In a separate study,
this pathway interaction was observed and linked to
behavioral phenotypes. Administration of Lactobacillus
reuteri normalized stress-induced behavioral changes andwas associated with decreased circulating kynurenine levels
resulting from microbially derived H2O2 inhibition of ido1
messenger RNA expression.98Neuroimmune Signaling
The wide-ranging interaction of commensal bacteria
with the gut-associated immune system and consequently
the CNS is beyond the scope of this review and has
been reviewed extensively elsewhere.99 Mouse models of
multiple sclerosis and stroke have identified substantial
roles for gut microbial regulation of autoimmunity,
inflammation, and immune cell trafficking.66,100–103 It is
important to highlight that the gut microbiota influence
the development and function of the CNS resident immune
cells, especially microglia.104 Relative to SPF mice, GF mice
have compromised microglia maturation and morphology,
leading to weakened early responses to pathogen expo-
sure.104 This phenotype can be normalized by postnatal
SCFA supplementation or colonization with a complex
microbial community. Remarkably, antibiotic treatment to
eradicate bacteria in SPF adult mice leads microglia to
2018 BGM Axis 137regain immature status, which then can be normalized by
recolonization with complex microbiota, suggesting that
active microbial signaling is required throughout adult-
hood to preserve microglial maturation.104
Direct Neural Signaling
Most evidence to date relies on vagal receptors that
sense regulatory gut peptides, inflammatory molecules,
dietary components, and bacterial metabolites to relay sig-
nals to the CNS,105 but there is also some evidence for direct
activation of neurons by gut microbiota. Toll-like receptors
3 and 7, which recognize viral RNA, and Toll-like receptors 2
and 4, which recognize peptidoglycan and lipopolysaccha-
ride, are expressed in the murine and human enteric ner-
vous systems.106,107 L rhamnosus (JB-1), B fragilis, and
isolated polysaccharide A of B fragilis all have been shown
to activate intestinal afferent neurons ex vivo.108 However,
it remains unclear to what degree luminal microbial anti-
gens make direct physical contact with neurons in vivo.109
Microbial metabolites also are likely candidates
mediating direct activation of neurons. The receptors FXR
and TGR5 are expressed in brain neurons, but bile acid
concentrations are low or undetectable in these tissues of
healthy subjects.110,111 Several studies have localized
GPR41/FFAR3 receptors to the superior cervical gan-
glion,112 prevertebral ganglia,113 submucosal and myenteric
ganglia neurons,114 sympathetic ganglia of the thoracic and
lumbar sympathetic trunks, and vagal ganglion,95 suggesting
neuronal activation by microbially derived SCFAs. Upon
GPR41 activation, primary-cultured superior cervical
neurons release norepinephrine, establishing this as a
direct functional interface for microbial derivatives and the
sympathetic nervous system.112
Barriers to Bottom-Up Signaling
There are 2 natural barriers to signaling within the BGM
axis: the intestinal barrier and the blood brain barrier.
Because gut microbes, stress, and inflammation are able to
modulate the permeability of both structures, the amount
of information reaching the brain from the gut is highly
variable, depending on the state of the host.
Intestinal Barrier
The intestinal barrier is characterized by 2 layers: a
basal monolayer of epithelial cells interconnected by tight
junctions, and a mucus layer whose thickness and compo-
sition changes over time and that contains secretory IgA and
antimicrobial peptides.115 Upon detection of specific mi-
crobial products, pattern recognition receptors located
throughout GI mucosa can mediate the induction of
enhanced antimicrobial defense, intestinal inflammation,
and even immunologic tolerance.116,117 Under healthy ho-
meostatic conditions, many microorganisms and macromol-
ecules gain entry through microfold cells (M cells), found in
gut- and mucosa-associated lymphoid tissue, which enables
constant sampling by immune cells.118 Paneth cells autono-
mously sense bacteria though MyD88-dependent Toll-like
receptor activation, which triggers antimicrobial factors andultimately limits bacterial penetration of host tissue.119
Microbes and microbe-derived ligands help maintain the
cell-cell junctions critical to integrity.120,121 Probiotic treat-
ment can help normalize stress-induced barrier defects
(discussed later) via unknown mechanisms.122
The intestinal mucus layer is the second component of
intestinal barrier function. Colonic mucus is organized into
2 layers: a thicker loose outer layer, and an inner layer
attached firmly to the epithelium.123 Commensal microbes
inhabit the outer layer, a critical habitat for biofilm for-
mation,124 and a reliable energy source rich in glycopro-
teins that the microbiota degrade when deprived of dietary
fiber, subsequently increasing pathogen susceptibility.11
The inner layer usually is bacteria-free and serves to
protect epithelial cells from microbial contact through
physical separation, innate immune mechanisms including
antimicrobial peptides, and adaptive immune mechanisms
including secretory IgA.125
Blood-Brain Barrier
The blood-brain barrier (BBB) regulates molecular
traffic between the circulatory system and the cerebrospi-
nal fluid of the CNS. Gut microbiota can up-regulate the
expression of tight junction proteins, including occludin
and claudin-5, therefore decreasing BBB permeability.126
From intrauterine life through adulthood, GF mice have a
more permeable barrier compared with controls, but
introduction of normal gut microbiota to GF adults partially
restores function. Permeability is decreased by mono-
colonization with SCFA-producing bacteria and oral gavage
with sodium butyrate. SCFAs may serve as the primary
signaling metabolite in BBB development and maintenance
likely via entering cells and working as histone deacetylase
inhibitors to epigenetically modulate the phenotype or via
binding to GPR41 and/or GPR43.127,128
Systemic immune activation may cause disruptive BBB
changes and often is modeled using LPS. But in a systematic
review, studies evaluating in vivo LPS effects on BBB function
only showed disruption 60% of the time, a figure potentially
subject to publication bias.129 Interestingly, the host species
is the only significant predictor explaining variance: mice are
4 times more likely than rats to show BBB change. Dose-
dependent effects were not observed across all studies,
although the levels used were mostly equivalent to septic
doses. The variability of the BBB response in this model of
systemic immune activation limits the generalizability of
most preclinical findings to human microbiome interactions,
especially in nonpathologic conditions.
Signaling From the Brain to the
Gut Microbiota
There is more than 40 years worth of literature showing
the effect of stress on the community structure of the gut
microbiome.130,131 Exposure to social stressors for as little
as 2 hours can change community profiles and reduce the
relative proportions of the primary phyla,132 and maternal
prenatal stress is associated with an altered infant micro-
biome potentiating increased inflammation.133
138 Martin et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 2Indirect Modulation via Autonomic
Nervous System–Mediated Change in
Microbial Environment
Both branches of the autonomic nervous system (ANS)
regulate gut functions including regional motility, secretion
of gastric acid, mucus, bicarbonate, gut peptides, antimi-
crobial peptides, epithelial fluid maintenance, intestinal
permeability, and mucosal immune response (reviewed by
Mayer1). These ANS-induced changes in gut physiology
affect the microbial habitat, thereby modulating microbiota
composition and activity.
GI Motility
Regional intestinal transit times affect water content,
nutrient availability, and bacterial clearance rates. Relatively
rapid flow in the small intestine inhibits permanent colo-
nization of the upper gut, in particular in the proximal small
intestine.124 The frequency of migrating motor complexes,
which play a crucial role in intestinal transit during the
fasting state, is influenced by food intake patterns, sleep
quality, and stress. Impaired migrating motor complex
regularity can reduce the flow rate, leading to small intes-
tine bacterial overgrowth.134 Intestinal transit time assessed
by the Bristol Stool Scale135,136 strongly correlates with
microbial richness and composition.137 In fact, a micro-
biome population level analysis identified such transit rat-
ings as the top nonredundant covariate.138 A study using
radiopaque markers for transit corroborated its association
to microbial composition and additionally showed associa-
tion with diversity and metabolism.139 In vitro simulation
with Environmental Controls Systems for Intestinal Micro-
biota showed that increased transit time causally reduced
bacterial biomass and diversity in distal gut regions.140
Intestinal Barrier
Stress can cause epithelial barrier defects (leaky gut) by
at least 2 mechanisms: direct modulation of epithelial
permeability and alterations in the properties of the
intestinal mucosal layer, ultimately leading to increased
translocation of gut microbes or microbe-associated mole-
cules.141 Rodent models have shown that jejunal and colonic
permeability increases in response to both acute and
chronic stress.142,143 This increased leakiness facilitates the
translocation of bacteria, such as Escherichia coli, and their
products, such as lipopolysaccharide (LPS), leading to a
proinflammatory environment in the gut, although there are
conflicting reports describing stress-induced changes in
expression of messenger RNA encoding tight junction pro-
teins in the colon and jejunum.144,145 Increased intestinal
permeability and susceptibility to experimental inflamma-
tion observed in mouse models of depressive behavior
induced by maternal separation is reversed by antidepres-
sant therapy, highlighting brain-driven systemic and
epithelial immune activity regulating the gut.146
The ANS modulates the secretion of mucus by intestinal
goblet cells, affecting the thickness and quality of the
intestinal mucus layer. In addition to hypersensitivity,
psychological stress leads to a less-protective mucus layervia catecholamine signaling, which alters the composition
and size of secreted mucus.122,147,148 Changes in microbiota
composition observed in a mouse model of brain injury are
thought to result from altered mucoprotein production
and goblet cell population size mediated by increased
sympathetic nervous system signaling.149,150Direct Modulation of Gut Microbiota by Luminal
Release of Neurotransmitters
In addition to CNS-induced changes in the intestinal
microbial environment (eg, by influencing regional transit
and secretions), the host neuroendocrine system can
communicate with the microbiota more directly via intra-
luminal release of host signaling molecules, including but
not limited to catecholamines, 5-HT, dynorphin, and cyto-
kines, from neurons, immune cells, and ECCs.151,152 The CNS
likely modulates this process.153–155 Epinephrine and
norepinephrine are shown to increase the virulence prop-
erties of several enteric pathogens as well as nonpathogenic
microbes via stimulation of native quorum-sensing mecha-
nisms.156–160 Other gut microbes contain sequences that
share 24% to 42% identity to human genome sequences for
the binding sites of melatonin,161 whose gut luminal con-
centrations have been reported at more than 10-fold serum
concentrations in rats and pigs.162,163 In vitro assays of one
such microbe, Enterobacter aerogenes, show that melatonin
not only induces swarming and motility behavior, but helps
synchronize the circadian period and phase across culture
plates.161 The gut microbiota show circadian rhythmicity in
both abundance and expression in a manner dependent on
the host and its behavior, especially feeding timing, and
simulated jet-lag shifts composition, enhancing dysbiosis.164
The BGM Axis in GI and Metabolic
Disorders
Functional Intestinal Disorders
A number of studies (n ¼ 22 in a total of 827 subjects)
have reported significant microbial shifts in fecal microbial
community composition between healthy controls and IBS
patients, based on disease subtypes (diarrhea-predominant
IBS, constipation-predominant IBS, and IBS mixed type),
age (pediatric vs adult), and compartment (mucosa vs
stool).165 Recent studies have suggested that there are at
least 2 subgroups of patients who meet Rome criteria for
IBS, based on gut microbial community structure, 1 sub-
group not differing from healthy control subjects, despite
similar GI symptoms.166,167 In one of these studies, the
dysbiotic IBS subgroup also differed in regional brain vol-
umes from the eubiotic group,166 suggesting a relationship
between microbial community structure and brain struc-
ture. Another recent study did not find a group difference in
microbial composition between HCs and IBS, even though
IBS symptom severity was correlated with dysbiosis.168
Despite a lack of consensus on the wide range of gut mi-
crobial differences between IBS subjects and healthy con-
trols and the specific microbial changes that may be
correlated to disease outcome, recent molecular-based
2018 BGM Axis 139methods of mucosal brushings or luminal aspirates have
suggested decreased diversity in small-bowel microbiota
with increased abundance of gram-negative organisms in
IBS.169,170 Based on analysis of fecal samples, regardless of
the analytical methodology used, a number of studies
reported a decreased relative abundance of the genera
Bifidobacterium and Lactobacillus, and an increased Firmi-
cutes:Bacteroidetes ratios at the phylum level. Because
stress has been associated with a reduction in Lactobacilli in
preclinical and clinical studies,132,171,172 one may speculate
that the reported IBS-related changes in community struc-
ture and resulting metabolism are in part owing to altered
ANS modulation of the gut as described earlier.
Obesity/Food Addiction
A dysregulation of hedonic feeding behavior (food
addiction) plays an important role in the current obesity
epidemic.173 The gut microbiota and its metabolites play an
crucial role in the modulation of satiety signals (see earlier)
and eating behaviors.65,174,175 In preclinical studies, fecal
transplantation from hyperphagic obese mice to germ-free
mice was able to induce hyperphagic behavior and weight
gain in the recipients.39,176 In addition, the gut microbiome
has been associated with changes in brain microstructure in
obesity, and distinct microbial brain signatures were able to
differentiate obese from lean subjects.177 The gut micro-
biome produces several neuroactive compounds; these
bioactive products include several indole-containing me-
tabolites and 5-HT. The administration of probiotics mod-
ifies brain function and even brain metabolites including
g-aminobutyric acid and glutamate.59,178 A handful of
studies point to a dramatic change in gut microbial
composition after bariatric surgery.179–183 Remarkably,
fecal transplantation from subjects after bariatric surgery
was able to transmit the weight loss effects of bariatric
surgery to a germ-free nonoperated recipient, inducing
weight loss and reduced food intake.184,185
The BGM Axis in Psychiatric
and Neurologic Disorders With
GI Comorbidities
Patients with several psychiatric (depression, anxiety)
and neurologic disorders (Parkinson’s disease, autism
spectrum disorders) have significant gastrointestinal
comorbidities, and several recent studies point to an
important role of the gut microbiota not only in the patho-
physiology of the GI symptoms, but a potential role in the
primary disorder as well.
Depression and Anxiety
Anxiety and depression often are comorbid conditions
in patients with IBS. Preclinical studies have shown the
microbiota’s capacity to modulate emotional behaviors,
and influence parameters significant to depression patho-
genesis and severity.17–19,21,186 Although studies charac-
terizing the gut microbiome of major depressive disorder
vs health have yielded marginally distinct assemblagecorrelations, 3 different types of studies suggest causality:
depressed human-to-rodent fecal microbial transplants
have induced depressive behaviors in the animal
models27,32; prebiotic and probiotic administration to
healthy controls has improved anxiety and mood; and,
finally, incidences of E coli subtype outbreaks in Canada
and Germany led to increases in depression and anxiety-
related symptoms among the affected population
(reviewed by Kelly et al186).
Parkinson’s Disease
Although the clinical hallmarks of Parkinson’s disease
remain motor deficits, gastrointestinal symptoms (in addition
to other nonmotor symptoms) are present that contribute
more detrimentally to patient quality of life. These nonmotor
symptoms include problems related to dysfunctional auto-
nomic and enteric nervous systems, such as slow-transit
constipation, and sensory alterations. The risk of Parkin-
son’s disease development increases with infrequency of
bowel movement and constipation severity, and there is a
significant comorbidity of Parkinson’s disease and IBS-like
symptoms.187 Moreover, constipation is among the earliest
features, appearing as early as 15.3 years before motor
dysfunction (reviewed by Fasano et al188). To date, clinical
studies of Parkinson’s and the gut microbiota remain limited
to characterizing the assemblage differences against healthy
controls, and some of the reported differences may be a
consequence of impaired colonic transit. However, recent
evidence showing that a Parkinson’s rodent model’s physical
impairments are enhanced by microbiota from Parkinson’s
patients but not healthy controls suggests causality.6 Early
gastrointestinal symptoms, thus, may be prodromal, making
the gut microbiota a promising source of information for
diagnosis, prognosis, and, potentially, pathogenesis.
Autism Spectrum Disorder
In addition to the core symptoms of ASD (difficulty with
social and communicative behavior, repetitive behaviors),
gastrointestinal symptoms are common and contribute
significantly to the morbidity of affected patients.5,189 GI
symptom severity is correlated strongly to ASD symptom
severity, as well as anxiety and sensory over-responsivity
conditions modulated by gut microbiota in preclinical
models (reviewed by Vuong and Hsiao5). Gut dysbiosis is an
increasingly documented symptom of ASD but, similar to
other clinical conditions, causality remains limited to
intriguing, albeit untested, hypotheses and results from
uncontrolled clinical studies.190
In summary, there is considerable and growing evidence
implicating the gut microbiome not only in the normal
development and function of the nervous system but also in
a range of acute and chronic diseases affecting the gut, as
well as the nervous system throughout life. It remains to be
determined if the gut microbiota play a causal role, but its
facilitation of pathogenesis and potentiation of severity in
disease models suggests that it is not merely a secondary
effect of the underlying etiology. In view of the extensive
preclinical evidence for both top-down and bottom-up
Figure 2. Systems biological model of brain-gut-microbiome interactions. The gut microbiota communicate with the gut
connectome, the network of interacting cell types in the gut that include neuronal, glial, endocrine, and immune cells,192 via
microbial metabolites, while changes in gut function can modulate gut microbial behavior. The brain connectome, the multiple
interconnected structural networks of the central nervous system,193 generates and regulates autonomic nervous system
influences that alter gut microbial composition and function indirectly by modulating the microbial environment in the gut. The
gut microbiota can communicate to the brain indirectly via gut-derived molecules acting on afferent vagal and/or spinal nerve
endings, or directly via microbe-generated signals. Alterations in the gain of these bidirectional interactions in response to
perturbations such as psychosocial or gut-directed (eg, diet, medication, infection) stress can alter the stability and behavior of
this system, manifesting as brain-gut disorders. Modified from Fung et al.99
140 Martin et al Cellular and Molecular Gastroenterology and Hepatology Vol. 6, No. 2signaling within the BGM axis and the emerging findings
from clinical studies, we propose a systems biological model
of bidirectional BGM interactions191 (Figure 2).Future
Despite considerable progress characterizing the interac-
tion between the gut microbiome and the CNS over the past
10 years, questions remain regarding their relevance to the
pathogenesis, pathophysiology, and treatment of human
brain gut disorders and we urge caution in prematurely
extrapolating findings in rodent models to human beings. For
example, based on clinical experience, long-term treatment
with broad-spectrum antibiotics for infectious diseases and
total colectomy in ulcerative colitis do not appear to have
noticeable effects on mood, affect, or cognition in the vast
number of patients. Advances in the field are the conse-
quence of ever-more-powerful biological techniques, such
as shotgun metagenomics and metatranscriptomics, coupledto novel bioinformatic and computational approaches that
enable multi-omic integration of both microbial and host data
using machine learning approaches. Efforts are underway not
only to characterize further microbial community structure,
function, and the contributions of individual taxa, but also the
large communities of viruses (virome) and fungi (myco-
biome) that, until recently, have been ignored owing to
technological limitations. The decreasing costs of novel multi-
omic analysis have facilitated data-driven approaches to
identify patient subgroups with distinct patterns of dysbiosis
and test the hypothesis that such subgroups will respond to
personalized therapy using dietary, prebiotic, or probiotic
interventions. However, there is an urgent need for large-
scale, highly controlled, longitudinal human studies
showing the causes and sequelae of dysbiotic gut states
and explaining interindividual variability in susceptibility
to BGM-related diseases. The past decade has shown a
potent hidden organ. This next decade will see widespread
inclusion of this newly discovered organ into diagnostic
2018 BGM Axis 141consideration and in targeted manipulation for therapeutic
intervention of many diseases.
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